1. Home
  2. KOP vs KROS Comparison

KOP vs KROS Comparison

Compare KOP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOP
  • KROS
  • Stock Information
  • Founded
  • KOP 1988
  • KROS 2015
  • Country
  • KOP United States
  • KROS United States
  • Employees
  • KOP N/A
  • KROS N/A
  • Industry
  • KOP Forest Products
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • KOP Basic Materials
  • KROS Health Care
  • Exchange
  • KOP Nasdaq
  • KROS Nasdaq
  • Market Cap
  • KOP 550.1M
  • KROS 565.0M
  • IPO Year
  • KOP 2006
  • KROS 2020
  • Fundamental
  • Price
  • KOP $26.34
  • KROS $16.09
  • Analyst Decision
  • KOP Strong Buy
  • KROS Buy
  • Analyst Count
  • KOP 2
  • KROS 14
  • Target Price
  • KOP $52.50
  • KROS $20.56
  • AVG Volume (30 Days)
  • KOP 179.9K
  • KROS 370.6K
  • Earning Date
  • KOP 11-07-2025
  • KROS 11-05-2025
  • Dividend Yield
  • KOP 1.21%
  • KROS N/A
  • EPS Growth
  • KOP N/A
  • KROS N/A
  • EPS
  • KOP 0.73
  • KROS 0.47
  • Revenue
  • KOP $1,992,600,000.00
  • KROS $232,844,000.00
  • Revenue This Year
  • KOP N/A
  • KROS $5,998.31
  • Revenue Next Year
  • KOP $2.35
  • KROS N/A
  • P/E Ratio
  • KOP $36.24
  • KROS $33.68
  • Revenue Growth
  • KOP N/A
  • KROS 85820.30
  • 52 Week Low
  • KOP $22.99
  • KROS $9.12
  • 52 Week High
  • KOP $39.83
  • KROS $72.37
  • Technical
  • Relative Strength Index (RSI)
  • KOP 31.03
  • KROS 53.30
  • Support Level
  • KOP $26.22
  • KROS $15.50
  • Resistance Level
  • KOP $28.07
  • KROS $16.57
  • Average True Range (ATR)
  • KOP 0.70
  • KROS 0.53
  • MACD
  • KOP -0.14
  • KROS -0.05
  • Stochastic Oscillator
  • KOP 8.12
  • KROS 48.41

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: